Transforming growth factor-beta-induced protein ig-h3; Beta ig-h3; Kerato-epithelin; RGD-containing collagen-associated protein; RGD-CAP; TGFBI; BIGH3

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit Ig

Rabbit

This TGFBI antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 106-135 amino acids from the N-terminal region of human TGFBI.

Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Maintain refrigerated at 2-8°C for up to 2 weeks,. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Small volumes of anti-TGFBI antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

This gene encodes an RGD-containing protein that binds to
type I, II and IV collagens. The RGD motif is found in many
extracellular matrix proteins modulating cell adhesion and serves
as a ligand recognition sequence for several integrins. This
protein plays a role in cell-collagen interactions and may be
involved in endochondrial bone formation in cartilage. The protein
is induced by transforming growth factor-beta and acts to inhibit
cell adhesion. Mutations in this gene are associated with multiple
types of corneal dystrophy.

Cancer; Cardiovascular; Developmental Biology; Neuroscience; Signal Transduction

Western Blot (WB), ELISA (EIA), Flow Cytometry (FC/FACS)

WB~~1:1000
FC~~1:10~50

Western blot analysis of TGFBI (arrow) using rabbit polyclonal TGFBI Antibody (N-term). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the TGFBI gene.

TGFBI Antibody (N-term) flow cytometric analysis of U251 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

transforming growth factor, beta-induced, 68kDa

transforming growth factor-beta-induced protein ig-h3

Transforming growth factor-beta-induced protein ig-h3

BIGH3; Beta ig-h3; RGD-CAP??[Similar Products]

BGH3_HUMAN

This gene encodes an RGD-containing protein that binds to type I, II and IV collagens. The RGD motif is found in many extracellular matrix proteins modulating cell adhesion and serves as a ligand recognition sequence for several integrins. This protein plays a role in cell-collagen interactions and may be involved in endochondrial bone formation in cartilage. The protein is induced by transforming growth factor-beta and acts to inhibit cell adhesion. Mutations in this gene are associated with multiple types of corneal dystrophy. [provided by RefSeq, Jul 2008]

betaIG-H3: Binds to type I, II, and IV collagens. This adhesion protein may play an important role in cell-collagen interactions. In cartilage, may be involved in endochondral bone formation. By TGFB1. Highly expressed in the corneal epithelium.

Protein type: Cell adhesion; Extracellular matrix; Secreted, signal peptide; Secreted

Chromosomal Location of Human Ortholog: 5q31

Cellular Component: extracellular matrix; extracellular space; proteinaceous extracellular matrix; plasma membrane; extracellular region; basement membrane; trans-Golgi network

Molecular Function: integrin binding; collagen binding; protein binding; extracellular matrix binding

Biological Process: cell proliferation; extracellular matrix organization and biogenesis; visual perception; response to stimulus; chondrocyte differentiation; negative regulation of cell adhesion; angiogenesis; cell adhesion

Disease: Corneal Dystrophy, Epithelial Basement Membrane; Corneal Dystrophy, Lattice Type Iiia; Corneal Dystrophy, Avellino Type; Corneal Dystrophy Of Bowman Layer, Type Ii; Corneal Dystrophy, Lattice Type I; Corneal Dystrophy Of Bowman Layer, Type I; Corneal Dystrophy, Groenouw Type I

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Edelstein, S.L., et al. Cornea 29(6):698-700(2010)
Romero, P., et al. Mol. Vis. 16, 1601-1609 (2010) :
Paliwal, P., et al. Mol. Vis. 16, 1429-1438 (2010) :
Yang, J., et al. Mol. Vis. 16, 1186-1193 (2010) :

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.